Balanced news tone
News Sentiment
KPRX sentiment intelligence
Kiora Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-4.6% over one week, -1.6% over four weeks, trend active, and below fair value.
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support Levels - Imbalance Zone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jun 2026 07:00
- Source
- DonanımHaber
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent Uptick - IV Spike
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- dars.gov.et
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 11:00
- Source
- TMX Newsfile
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Apr 2026 11:12
- Source
- TMX Newsfile
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Apr 2026 07:00
- Source
- StocksToTrade
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
KPRX Stock Price and Chart — NASDAQ:KPRX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2024 07:00
- Source
- TradingView
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 Jan 2024 08:00
- Source
- TMX Newsfile
Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Nov 2021 10:15
- Source
- MarketBeat